• PD0325901: MEK Inhibitor Workflows for Cancer Research

  2026-09-23

  Use PD0325901 to test MEK-dependent signaling, connect ERK suppression to cell-cycle and apoptosis readouts, and build a controlled cancer-model workflow. Practical guidance distinguishes product-supported findings from proposed pilot conditions—and explains how a new study of translation termination can inform assay design without implying an unproven link to MEK.

• Isorhamnetin: A Mechanism-First Assay Guide

  2026-09-23

  Isorhamnetin is a flavonoid research compound for investigating oxidative stress, apoptosis, and PI3K/Akt-dependent cellular responses. This guide moves beyond a single efficacy result to show how chemical handling, orthogonal readouts, and pathway interpretation can produce more rigorous assays.

• ARID1A-Driven Resistance in Melanoma: Multi-Omics Insights

  2026-09-22

  The reference study integrates early signaling, molecular abundance, and network-level data to explain how ARID1A loss reshapes melanoma responses to BRAF/MAPK inhibition. Its identification of PRKD1, JUN, and NCK1 as resistance-associated nodes provides a focused framework for validating adaptive signaling, immune-related changes, and therapeutic vulnerabilities.

• Psoralen-Induced Cholestasis via ERK1/2

  2026-09-22

  Chen and colleagues show that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, cause cholestatic liver injury in zebrafish larvae through disrupted bile acid regulation and increased ERK1/2 phosphorylation. Pharmacological rescue with exemestane and GDC-0994 links estrogenic signaling and ERK activity to the phenotype, identifying ERK1/2 as a mechanistic target for further cholestasis research.

• Selonsertib (GS-4997) for Oxidative Stress Assays

  2026-09-21

  Use Selonsertib (GS-4997) to separate ASK1-dependent stress signaling from the broader autophagy and metabolic phenotypes observed in hepatic steatosis models. This workflow pairs selective kinase perturbation with p38/JNK, autophagic-flux, lipid-accumulation, and insulin-response readouts for more defensible mechanism studies.

• Psoralen, Isopsoralen, and ERK1/2 Cholestasis

  2026-09-21

  A 2024 Chemical Research in Toxicology study connected the phytoestrogens psoralen and isopsoralen to estrogen-like signaling, altered bile-acid regulation, and ERK1/2 activation in zebrafish larvae. Its combination of functional liver phenotyping, gene-expression analysis, phosphorylation measurements, and pharmacological rescue provides a mechanistic framework for studying phytoestrogen-associated cholestasis.

• AG-120 (Ivosidenib): From 2-HG to Assay Strategy

  2026-09-20

  AG-120 and Ivosidenib provide a precise way to connect mutant IDH1 inhibition with 2-hydroxyglutarate reduction, differentiation, and metabolic dependency. This article presents an assay-centered framework for interpreting AML responses and translating CD44-linked findings into stronger experimental designs.

• 4-Ethylphenyl Sulfate: Assay Workflows

  2026-09-19

  Learn how 4-ethylphenyl sulfate can support renal biomarker assays, metabolite-surface adsorption studies, and gut microbiota-brain interaction research. This workflow-focused guide emphasizes matrix controls, mass-spectrometry readiness, storage, and troubleshooting for more reproducible results.

• CCR5-Positive EVs in Rheumatoid Arthritis

  2026-09-18

  The reference study identifies CCR5-bearing extracellular vesicles released by rheumatoid arthritis synovial fibroblasts as active mediators of cartilage destruction, bone erosion, and NF-κB-associated inflammation. Its combined in vitro and adjuvant-induced arthritis experiments suggest that removing or pharmacologically blocking EV-associated CCR5 can reduce pathogenic signaling, while also defining important limits for translating this mechanism into therapy.

• GDC-0994: ERK1/2 Inhibitor Workflow Guide

  2026-09-18

  GDC-0994 provides a selective way to test whether ERK1/2 signaling drives tumor cell proliferation or estrogen-associated cholestatic injury. This practical guide connects target-engagement assays, zebrafish liver models, oncology workflows, and troubleshooting strategies around one experimentally tractable ERK pathway inhibitor.

• EX 527 for SIRT1 Mechanism Studies

  2026-09-17

  EX 527 (SEN0014196) enables selective interrogation of SIRT1 catalytic activity across p53, DNA-damage, vascular, and osteogenic models. Its biochemical potency and strong selectivity over SIRT2 and SIRT3 make it useful for separating SIRT1-dependent phenotypes from broader sirtuin effects.

• PD0325901: Reliable MEK Inhibition Workflows

  2026-09-17

  This scenario-driven guide explains how PD0325901 (SKU A3013) can improve interpretation of viability, proliferation, cytotoxicity, and pathway-inhibition assays. It connects practical stock preparation, orthogonal readouts, experimental controls, and vendor-selection criteria with documented MEK, cell-cycle, apoptosis, and xenograft findings.

• Arrb2, 6-ketoLCA, and Hepatic IRI

  2026-09-16

  The reference study identifies hepatocyte Arrb2 as a regulator of macrophage behavior during hepatic ischemia–reperfusion injury, connecting increased 6-ketoLCA with M2 polarization and reduced tissue damage. Its combination of clinical samples, hepatocyte-focused mouse genetics, hypoxia–reoxygenation experiments, and metabolite analysis offers a useful framework for mechanistic liver transplantation research.

• Capsaicin C6366 for Reliable Cell Assays

  2026-09-16

  Capsaicin (SKU C6366) supports better-controlled viability, proliferation, cytotoxicity, and sensory-neuron workflows by linking documented TRPV1 activity with KDM1A/LSD1 inhibition. This guide addresses dose selection, solvent compatibility, endpoint interpretation, and practical supplier evaluation using quantitative product data.

• LGK-974: From Wnt Gradients to Better Assays

  2026-09-15

  Explore how LGK-974, a selective PORCN inhibitor, converts Wnt secretion biology into a precise experimental strategy. This article connects developmental Wnt patterning in hemichordates with assay design for Wnt-dependent cancer and pancreatic cancer RNF43 mutation research.

8662 records 1/578 page Next 12345 下5页 Last page